(Q36655244)

15 August 2017

1 reference

title

Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review (English)

1 reference

15 August 2017

1 reference

Jean-Marc Idée

1

1 reference

15 August 2017

Marc Port

2

1 reference

15 August 2017

Isabelle Raynal

3

1 reference

15 August 2017

Michel Schaefer

4

1 reference

15 August 2017

Soizic Le Greneur

5

1 reference

15 August 2017

Claire Corot

6

1 reference

15 August 2017

1 December 2006

1 reference

Fundamental and Clinical Pharmacology

15 August 2017

1 reference

15 August 2017

20

1 reference

15 August 2017

6

1 reference

15 August 2017

563-576

1 reference

Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Currently used non-specific extracellular MR contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Contrast agents for magnetic resonance imaging: safety update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Adverse reactions to gadolinium contrast media: a review of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Magnetic resonance contrast agents: from the bench to the patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Structure of angiotensin I-converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Safety assessment of gadoversetamide (OptiMARK) administered by power injector

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Clinical manifestations of zinc deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Tolerance data of Gd-DTPA: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Amelioration of cardiodepressive effects of gadopentetate dimeglumine with addition of ionic calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

The effect of gadolinium-based MRI contrast agents on the biodistribution of (67)Ga

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

More on Pseudohypocalcemia and Gadolinium-Enhanced MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2006.00447.X

10.1111/J.1472-8206.2006.00447.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference